Saluda Medical lists on Friday, having raised $230 million The funds will support the US rollout of Saluda’s Evoke spinal cord stimulation device The listing will be only the fourth ASX biotech debut ...
The Evoke ® System is the First SCS System to Demonstrate Cost-Dominance at Two Years Post-Implant MINNEAPOLIS, Aug. 4, 2023 /PRNewswire/ -- Saluda Medical, Inc. ("Saluda Medical"), a global medical ...
MINNEAPOLIS, July 17, 2025 /PRNewswire/ -- Saluda Medical, Inc., a pioneer in the development and commercialization of a novel neuromodulation platform designed to transform the lives of patients with ...
In the case of Saluda Medical, investors should momentarily cast their gaze away from the IPO candidate’s prospectus, to the pages of the humble Mornington Peninsula News. The Victorian regional bugle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback